Sunitinib inhibits the phosphorylation of platelet‐derived growth factor receptor β in the skin of mice with scleroderma‐like features and prevents the development of the disease

Abstract

Inhibition of the hyperactivated PDGF and VEGF pathways by sunitinib prevented the development of fibrosis in HOCl-induced murine SSc and may represent a new SSc treatment for testing in clinical trials.